Vanguard Group Inc. lifted its position in shares of Masimo Co. (NASDAQ:MASI) by 0.6% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 4,449,405 shares of the medical equipment provider’s stock after acquiring an additional 27,580 shares during the quarter. Vanguard Group Inc. owned approximately 8.34% of Masimo worth $662,160,000 at the end of the most recent reporting period.
Several other hedge funds have also recently added to or reduced their stakes in MASI. FMR LLC raised its position in shares of Masimo by 7.4% during the first quarter. FMR LLC now owns 4,178,808 shares of the medical equipment provider’s stock worth $577,845,000 after acquiring an additional 289,246 shares during the last quarter. OppenheimerFunds Inc. raised its position in shares of Masimo by 131.1% during the first quarter. OppenheimerFunds Inc. now owns 412,968 shares of the medical equipment provider’s stock worth $57,105,000 after acquiring an additional 234,236 shares during the last quarter. Handelsbanken Fonder AB bought a new stake in shares of Masimo during the second quarter worth $19,867,000. Janus Henderson Group PLC raised its position in shares of Masimo by 17.2% during the second quarter. Janus Henderson Group PLC now owns 691,953 shares of the medical equipment provider’s stock worth $102,976,000 after acquiring an additional 101,354 shares during the last quarter. Finally, APG Asset Management N.V. raised its position in shares of Masimo by 152.1% during the second quarter. APG Asset Management N.V. now owns 134,900 shares of the medical equipment provider’s stock worth $17,629,000 after acquiring an additional 81,400 shares during the last quarter. Institutional investors own 83.07% of the company’s stock.
In related news, CEO Joe E. Kiani sold 100,000 shares of the company’s stock in a transaction dated Monday, July 1st. The stock was sold at an average price of $150.14, for a total value of $15,014,000.00. Following the completion of the sale, the chief executive officer now owns 239,241 shares in the company, valued at $35,919,643.74. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Joe E. Kiani sold 18,437 shares of the company’s stock in a transaction dated Friday, July 26th. The shares were sold at an average price of $160.02, for a total value of $2,950,288.74. Following the completion of the sale, the chief executive officer now owns 157,678 shares of the company’s stock, valued at approximately $25,231,633.56. The disclosure for this sale can be found here. Insiders sold 206,691 shares of company stock valued at $31,581,145 in the last quarter. 11.50% of the stock is currently owned by corporate insiders.
NASDAQ MASI traded down $0.33 on Wednesday, reaching $148.94. The company had a trading volume of 146,571 shares, compared to its average volume of 346,461. The stock’s 50 day moving average is $151.75 and its 200-day moving average is $143.18. The stock has a market cap of $7.93 billion, a price-to-earnings ratio of 49.16, a PEG ratio of 2.02 and a beta of 1.22. Masimo Co. has a 52 week low of $98.23 and a 52 week high of $160.25.
Masimo (NASDAQ:MASI) last released its quarterly earnings data on Wednesday, July 31st. The medical equipment provider reported $0.76 EPS for the quarter, beating analysts’ consensus estimates of $0.73 by $0.03. The business had revenue of $229.60 million during the quarter, compared to the consensus estimate of $222.46 million. Masimo had a return on equity of 17.82% and a net margin of 22.15%. The firm’s revenue was up 8.5% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.73 earnings per share. As a group, equities research analysts predict that Masimo Co. will post 3.15 earnings per share for the current fiscal year.
Masimo Corporation, a medical technology company, develops, manufactures, and markets noninvasive monitoring technologies worldwide. The company offers Masimo Signal Extraction Technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry.
Further Reading: Basic Economics creates winners and losers
Receive News & Ratings for Masimo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo and related companies with MarketBeat.com's FREE daily email newsletter.